Citations

Showing 10 of 108083 citations.

Grooveplasty Compared With Trochleoplasty for the Treatment of Trochlear Dysplasia in the Setting of Patellar Instability
Reinholz, Anna K., Till, Sara E., Crowe, Matthew M. , Hevesi, Mario , Saris, Daniël B.F. , Stuart, Michael J. , Krych, Aaron J. , Krych, Aaron J , Stuart, Michael J , Hevesi, Mario

Mayo Clinic

Arthroscopy, Sports Medicine, and Rehabilitation | December 26, 2022 | Volume: 5 | Issue: 1 | Pages: No page available

10.1016/j.asmr.2022.11.020 | PMID 36866307 Get It

Purpose To compare the clinical efficacy in the resolution of patellar instability, patient‐reported outcomes (PROs), and complication and reoperation rates between patients who underwent grooveplasty (proximal trochleoplasty) and patients who underwent trochleoplasty as part of a combined patellofemoral stabilization procedure. Methods A retrospective chart review was performed to identify a cohort of patients who underwent grooveplasty and a cohort who underwent trochleoplasty at the time of patellar stabilization. Complications, reoperations, and PRO scores (Tegner, Kujala, and International Knee Documentation Committee scores) were collected at final follow‐up. The Kruskal‐Wallis test and Fisher exact test were performed when appropriate, and P < .05 was considered significant. Results Overall, 17 grooveplasty patients (18 knees) and 15 trochleoplasty patients (15 knees) were included. Seventy‐nine percent of patients were female, and the average follow‐up period was 3.9 years. The mean age at first dislocation was 11.8 years overall; most patients (65%) had more than 10 lifetime instability events and 76% of patients underwent prior knee‐stabilizing procedures. Trochlear dysplasia (Dejour classification) was similar between cohorts. Patients who underwent grooveplasty had a higher activity level ( P = .007) and a higher degree of patellar facet chondromalacia ( P = .008) at baseline. At final follow‐up, no patients had recurrent symptomatic instability after grooveplasty compared with 5 patients in the trochleoplasty cohort ( P = .013). There were no differences in postoperative International Knee Documentation Committee scores ( P = .870), Kujala scores ( P = .059), or Tegner scores ( P = .052). Additionally, there were no differences in complication rates (17% in grooveplasty cohort vs 13% in trochleoplasty cohort, P > .999) or reoperation rates (22% vs 13%, P = .665). Conclusions Proximal trochlear reshaping and removal of the supratrochlear spur (grooveplasty) in patients with severe trochlear dysplasia may offer an alternative strategy to complete trochleoplasty for the treatment of trochlear dysplasia in complex cases of patellofemoral instability. Grooveplasty patients showed less recurrent instability and similar PROs and reoperation rates compared with trochleoplasty patients. Level of Evidence Level III, retrospective comparative study.
The risks of cancer in older women with BRCA pathogenic variants: How far have we come?
Metcalfe, Kelly , McCuaig, Jeanna , Eisen, Andrea , Elser, Christine , Senter, Leigha , Møller, Pål , Bordeleau, Louise , Velsher, Lea, Zakalik, Dana , Olopade, Olufunmilayo I. , Cullinane, Carey A., Sun, Ping , Narod, Steven A. , Metcalfe, Kelly A , Olopade, Olufunmilayo I , Kotsopoulos, Joanne , Narod, Steven A , Senter, Leigha , Eisen, Andrea , Bordeleau, Louise , Gronwald, Jacek , Tung, Nadine , Foulkes, William D. , Neuhausen, Susan L. , Fruscio, Robert , Eng, Charis , Pal, Tuya , Couch, Fergus J. , Kotsopoulos, Joanne , Lubiński, Jan

Mayo Clinic

Cancer | December 26, 2022 | Volume: 129 | Issue: 6 | Pages: 901-907

10.1002/cncr.34615 | PMID 36571512 Get It

AbstractBackgroundThe purpose of this study was to estimate the cumulative risks of all cancers in women from 50 to 75 years of age with a BRCA1 or BRCA2 pathogenic variant.MethodsParticipants were women with BRCA1 or BRCA2 pathogenic variants from 85 centers in 16 countries. Women were eligible if they had no cancer before the age of 50 years. Participants completed a baseline questionnaire and follow‐up questionnaires every 2 years. Women were followed from age 50 until a diagnosis of cancer, death, age 75, or last follow‐up. The risk of all cancers combined from age 50 to 75 was estimated using the Kaplan–Meier method.ResultsThere were 2211 women included (1470 BRCA1 and 742 BRCA2). There were 379 cancers diagnosed in the cohort between 50 and 75 years. The actuarial risk of any cancer from age 50 to 75 was 49% for BRCA1 and 43% for BRCA2. Breast (n = 186) and ovarian (n = 45) were the most frequent cancers observed. For women who had both risk‐reducing mastectomy and bilateral salpingo‐oophorectomy before age 50, the risk of developing any cancer between age 50 and 75 was 9%.ConclusionWomen with a BRCA1 or BRCA2 pathogenic variant have a high risk of cancer between the ages of 50 and 75 years and should be counselled appropriately.
Development and validation of a recursive partitioning analysis–based pretreatment decision‐making tool identifying ideal candidates for spine stereotactic body radiation therapy
Kowalchuk, Roman O. , Mullikin, Trey C. , Florez, Marcus A. , De, Brian , Spears, Grant M. , Rose, Peter S. , Kim, Dong Kun , Costello, Brian A. , Marion, Joseph , Johnson‐Tesch, Benjamin A., Gao, Robert W. , Shiraishi, Satomi , Lucido, J. John , Olivier, Kenneth R. , Owen, Dawn , Stish, Bradley J. , Waddle, Mark R. , Brown, Paul D. , Ghia, Amol J. , Merrell, Kenneth W. , Marion, Joseph T , Johnson-Tesch, Benjamin A, Lucido, John J , Trifiletti, Daniel M , Waddle, Mark R , Brown, Paul D , Merrell, Kenneth W , Kowalchuk, Roman O. , Shiraishi, Satomi , Siontis, Brittany L. , Morris, Jonathan M. , Trifiletti, Daniel M. , Laack, Nadia N. , Park, Sean S.

Mayo Clinic

Cancer | December 26, 2022 | Volume: 129 | Issue: 6 | Pages: 956-965

10.1002/cncr.34626 | PMID 36571507 Get It

AbstractBackgroundThis study was aimed at developing and validating a decision‐making tool predictive of overall survival (OS) for patients receiving stereotactic body radiation therapy (SBRT) for spinal metastases.MethodsThree hundred sixty‐one patients at one institution were used for the training set, and 182 at a second institution were used for external validation. Treatments most commonly involved one or three fractions of spine SBRT. Exclusion criteria included proton therapy and benign histologies.ResultsThe final model consisted of the following variables and scores: Spinal Instability Neoplastic Score (SINS) ≥ 6 (1), time from primary diagnosis < 21 months (1), Eastern Cooperative Oncology Group (ECOG) performance status = 1 (1) or ECOG performance status > 1 (2), and >1 organ system involved (1). Each variable was an independent predictor of OS (p < .001), and each 1‐point increase in the score was associated with a hazard ratio of 2.01 (95% confidence interval [CI], 1.79–2.25; p < .0001). The concordance value was 0.75 (95% CI, 0.71–0.78). The scores were discretized into three groups—favorable (score = 0–1), intermediate (score = 2), and poor survival (score = 3–5)—with 2‐year OS rates of 84% (95% CI, 79%–90%), 46% (95% CI, 36%–59%), and 21% (95% CI, 14%–32%), respectively (p < .0001 for each). In the external validation set (182 patients), the score was also predictive of OS (p < .0001). Increasing SINS<zaq;6> was predictive of decreased OS as a continuous variable (p < .0001).ConclusionsThis novel score is proposed as a decision‐making tool to help to optimize patient selection for spine SBRT. SINS may be an independent predictor of OS.
Deep Brain Stimulator Device Infection: The Mayo Clinic Rochester Experience
Tabaja, Hussam , Tai, Don Bambino Geno , Chesdachai, Supavit , Hassan, Anhar , Klassen, Bryan T. , Miller, Kai J. , Lee, Kendall H. , Yuen, Jason , Campioli, Cristina Corsini , Mahmood, Maryam , Chesdachai, Supavit , Tai, Don Bambino Geno , Tabaja, Hussam , DeSimone, Daniel C. , Mahmood, Maryam

Mayo Clinic

Open Forum Infectious Diseases | December 26, 2022 | Volume: 10 | Issue: 1 | Pages: No page available

10.1093/ofid/ofac631 | PMID 36632420 Get It

Abstract Background Deep brain stimulator (DBS)–related infection is a recognized complication that may significantly alter the course of DBS therapy. We describe the Mayo Clinic Rochester experience with DBS-related infections. Methods This was a retrospective study of all adults (≥18 years old) who underwent DBS-related procedures between 2000 and 2020 at the Mayo Clinic Rochester. Results There were 1087 patients who underwent 1896 procedures. Infection occurred in 57/1112 (5%) primary DBS implantations and 16/784 (2%) revision surgeries. The median time to infection (interquartile range) was 2.1 (0.9–6.9) months. The odds of infection were higher with longer operative length (P = .002), higher body mass index (BMI; P = .006), male sex (P = .041), and diabetes mellitus (P = .002). The association between infection and higher BMI (P = .002), male sex (P = .016), and diabetes mellitus (P = .003) remained significant in a subgroup analysis of primary implantations but not revision surgeries. Infection was superficial in 17 (23%) and deep in 56 (77%) cases. Commonly identified pathogens were Staphylococcus aureus (65%), coagulase-negative staphylococci (43%), and Cutibacterium acnes (45%). Three device management approaches were identified: 39 (53%) had complete device explantation, 20 (27%) had surgical intervention with device retention, and 14 (19%) had medical management alone. Treatment failure occurred in 16 (23%) patients. Time-to-event analysis showed fewer treatment failures with complete device explantation (P = .015). Only 1 individual had complications with brain abscess at failure. Conclusions Primary DBS implantations had higher rates of infection compared with revision surgeries. Complete device explantation was favored for deep infections. However, device salvage was commonly attempted and is a reasonable approach in select cases given the low rate of complications.
Abductor Pollicis Longus Tendon Abnormalities and Release in Children With Congenital Clasped Thumb
Israel, Jacqueline S. , Jeardeau, Teresa A., Tomhave, Wendy , Moran, Steven L. , Jeardeau, Teresa A.

Mayo Clinic

HAND | December 26, 2022 | Volume: 19 | Issue: 5 | Pages: 790-799

10.1177/15589447221141475 | PMID 36571390 Get It

Background: Congenital clasped thumb is associated with deficient thumb extensor tendons. Reconstruction includes tendon transfer. Here, we describe a variant of the abductor pollicis longus (APL) tendon, not previously reported, contributing to the flexion deformity. The purpose of this study is to report examples of and offer surgical repair techniques for APL variants identified in patients with clasped thumb. Methods: We reviewed records of 11 consecutive patients undergoing reconstruction for clasped thumb. Surgical anatomy of the APL tendon was evaluated in all patients, followed by release of aberrant APL attachments. Participants were invited to return for an in-person assessment with a certified hand therapist. Data were collected regarding intraoperative findings, surgical techniques for reconstruction, postoperative thumb motion, and patient and caregiver satisfaction. Results: Eleven children (12 thumbs) underwent aberrant APL release and rerouting between 2019 and 2021. Preoperatively, all thumbs were passively correctible to 0° of extension. In all patients, the APL was found to terminate palmar to the metacarpophalangeal (MCP) joint, creating an MCP flexion moment when tensioned. The average age at surgery was 7 years (range: 1-15 years), and the average follow-up was 14.2 months (range: 1-21 months). The mean postoperative thumb radial abduction was 55° (range: 20°-75°). Conclusions: When reconstructing clasped thumbs, surgeons should explore the presence of APL abnormalities. Release and centralization of the APL can improve thumb position and function. This technique may avoid the need for extra-anatomical tendon transfer in patients with clasped thumb.
Vocal Fold Pathologies Among Undergraduate Singing Students In Three Different Genres
Bretl, Michelle , Gerhard, Julia , Rosow, David E. , Anis, Mursalin M. , Landera, Mario A., Libman, Dana R., Marchman, Judy O., Ragsdale, Frank Wayne, Moore, Stephannie, Ma, Ruixuan , Hoffman, Bari , Ivey, Chandra M. , Johns, Michael M. , Menton, Stacey M., Lloyd, Adam , Bretl, Michelle M , Anis, Mursalin , Ivey, Chandra , Lloyd, Adam T , Moore, Stephannie, Menton, Stacey M.

Mayo Clinic

The Laryngoscope | December 26, 2022 | Volume: 133 | Issue: 9 | Pages: 2317-2324

10.1002/lary.30533 | PMID 36567624 Get It

ObjectiveThis study aimed to compare the prevalence and incidence of vocal fold pathologies among undergraduate classical, musical theatre, and contemporary commercial music (CCM) students over two‐time points.MethodsThis study is part of a longitudinal investigation. Videostroboscopic examinations were rated, with consensus among three of four expert blinded raters confirming the presence of pathology. Association between genre of singer and the presence of pathology, interrater reliability, and intra‐rater reliability were calculated. Prevalence and incidence of pathologies were compared across genres.ResultsDuring first‐year evaluations, 32% of musical theatre, 18% of CCM, and 0% of classical students had vocal pathologies. The prevalence at third‐year evaluations showed 22% of classical, 39% of musical theatre, and 27% of CCM participants having vocal fold pathologies. The incidence of pathologies was 67% of musical theatre students compared to 22% of classical students and 27% of CCM students. The four raters demonstrated fair to moderate interrater agreement. Singing Voice Handicap Index‐10 scores were normal for CCM singers at both time points but elevated for musical theatre and classical singers.ConclusionNo classical singers were found to have pathology during first‐year evaluations, although CCM and musical theatre singers showed evidence of vocal fold pathologies. At third‐year evaluations, all three genres had an apparent increase in prevalence of pathologies. Implications of this study suggest that more time in the field and intense voice usage may lead to a greater risk of pathology for all singers, regardless of genre.Level of Evidence2 Laryngoscope, 133:2317–2324, 2023
Report of A Family with Adult‐Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Without Mutations in CSF1R, AARS1 or AARS2
Dulski, Jarosław , Koga, Shunsuke , Koga, Shunsuke , Dulski, Jaroslaw , Dickson, Dennis W. , Wszołek, Zbigniew K.

Mayo Clinic

Movement Disorders Clinical Practice | December 26, 2022 | Volume: 10 | Issue: 2 | Pages: 307-312

10.1002/mdc3.13650 | PMID 36825047 Get It

ABSTRACTBackgroundAdult‐onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) is a rare neurodegenerative disorder with characteristic clinicopathological features. Identification of pathogenic mutations in CSF1R, AARS1, and AARS2 genes led to increased recognition and diagnosis of the ALSP.ObjectivesThis paper presents the first family with typical clinical, radiological, and pathological features of ALSP, yet negative for CSF1R, AARS1, and AARS2 mutations.MethodsThe index case was a 30‐year‐old male who presented with gait difficulty, followed by cognitive decline and incontinence.ResultsNeurological examination evidenced progressive dementia, dysarthria, spasticity, parkinsonism, and severe gait disturbances. Brain MRI showed confluent white matter abnormalities with scattered foci of restricted diffusion, and atrophy of the corpus callosum. He was suspected of ALSP; however, the extensive genetic work‐up did not find pathogenic mutation. He died at 33 years, and brain autopsy was performed. He had myelin staining pallor and axonal swellings, spheroids, and pigmented glia in affected white matter. His father developed similar symptoms in his early 40s and died at 46 years. Neuropathological examination also confirmed ALSP diagnosis. We found two similar cases in the literature with typical ALSP features but negative for CSF1R mutation; however, none were tested for AARS1 and AARS2 mutations.ConclusionsWe draw attention to a new entity within the ALSP disease spectrum that needs further investigation. As the disease‐modifying therapy is already available for ALSP‐CSF1R, there is a strong need to identify the genetic cause of patients such as these in the ALSP spectrum, enabling research toward implementing effective treatment.
Exercise and the Brain in Cardiovascular Disease: A Narrative Review
Taylor, Jenna L. , Taylor, Jenna L

Mayo Clinic

Heart and Mind | December 25, 2022 | Volume: 7 | Issue: 1 | Pages: 5-12

10.4103/hm.hm_50_22 Get It

Patients with cardiovascular diseases (CVDs) (including heart failure) are at increased risk of cognitive impairment and dementia. Vascular risk factors contribute to cognitive decline through cerebral small vessel diseases, pathological brain changes, and hypoperfusion. Habitual exercise and increased cardiorespiratory fitness are associated with higher cognitive function, greater cerebral blood flow, and attenuation of the decline in gray matter volume and white matter integrity. Furthermore, moderate-vigorous exercise training has been shown to improve cognitive function in healthy middle-aged and older adults. Cardiac rehabilitation (CR) is a class 1A recommendation for patients with CVD, which involves exercise training and intensive risk factor modification. This article reviews the current evidence for the effect of exercise-based CR on cognitive function, cerebrovascular function, and brain structure in patients with CVDs. Overall, exercise-based CR appears to improve global cognitive function and attention-psychomotor functions but not language processes. Furthermore, the effect of exercise-based CR on executive function and memory is less clear and there is limited research into the effect of exercise-based CR on cerebrovascular function and brain structure.
Pharmacist adjustment of preoperative antibiotic orders to the preferred preoperative antibiotic cefazolin for patients with penicillin allergy labeling
Lessard, Sarah , Huiras, Chris, Dababneh, Ala S. , Palraj, Raj , Thies, Renee, Woolever, Nate, Holt, Kandi, Schwan, Brenda, Poelma, Jennifer, Tempelis, Jennifer, Sawyer, Mark H., Dababneh, Ala, Sawyer, Mark, Palraj, Raj , Sawyer, Mark

Mayo Clinic

American Journal of Health-System Pharmacy | December 25, 2022 | Volume: 80 | Issue: 8 | Pages: 532-536

10.1093/ajhp/zxac385 | PMID 36566496 Get It

AbstractPurposeEmerging literature has detailed the safe use of cefazolin in patients with immunoglobulin E–mediated penicillin allergy labeling (PAL) such as hives and anaphylaxis. The purpose of this article is to detail efforts led by an antimicrobial stewardship pharmacist working with an interdisciplinary team to optimize preoperative antimicrobials in patients with PAL.MethodsA pharmacist-led, interdisciplinary collaborative practice agreement (CPA) was activated in January 2020 to permit pharmacists to independently optimize preoperative antibiotics to the preferred cefazolin in patients with PAL if nonsevere or severe reactions had been reported. A patient registry was established covering the timeframe between January 8, 2020, and January 6, 2022. Reaction during surgery was assessed via 2-provider documentation, which included surgeon and anesthesiology staff documentation of any complications during the procedure related to a suspected allergic safety event. Utilization of cefazolin, clindamycin, and vancomycin for preoperative prophylaxis was monitored before and after implementation of the CPA.ResultsDuring the stated timeframe, 10,182 procedures and/or surgeries were completed on 1,572 (15.4%) patients with PAL and 659 (41.9%) patients previously reporting at least one reaction categorized as a severe reaction, which was hives for 71.2% of these patients. Of the 659 patients with PAL reporting a severe reaction, 356 received a preoperative cephalosporin (cefazolin, 98.8%; ceftriaxone, 1.2%) and tolerated it without a reported safety event, including 52 patients with PAL previously reporting anaphylaxis. An increase in preferred preoperative antimicrobial prophylaxis utilization was noted (cefazolin: 86% to 96.3%, P &lt; 0.001; 2019 to 2021) with reductions noted in the use of nonpreferred preoperative antibiotics (clindamycin: 2.1% to 0.2%, P &lt; 0.001; vancomycin: 3.2% to 0.4%, P &lt; 0.001; 2019 to 2021).ConclusionA pharmacist-led, interdisciplinary CPA increased preferred preoperative antimicrobial use in patients with PAL reporting severe allergic reactions, including hives and anaphylaxis, without reported safety events.